1. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome.
- Author
-
Lian J, Tang X, Gui Y, Lu S, Song Y, and Deng Y
- Subjects
- Animals, Male, Rats, Sprague-Dawley, Rats, Phosphatidylethanolamines chemistry, Disease Models, Animal, Doxorubicin analogs & derivatives, Doxorubicin pharmacokinetics, Doxorubicin administration & dosage, Doxorubicin adverse effects, Polyethylene Glycols chemistry, Polyethylene Glycols pharmacokinetics, Polyethylene Glycols administration & dosage, Liposomes, Hand-Foot Syndrome etiology, Antibiotics, Antineoplastic pharmacokinetics, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic adverse effects
- Abstract
PEGylated liposomal doxorubicin (PLD) has effectively reduced the cardiac toxicity of free doxorubicin (DOX) due to its unique nanoscale properties. However, an unexpected accumulation of PLD in the skin has led to hand-foot syndrome (HFS), negatively impacting quality of life and psychological well-being. In this study, self-limiting HFS rat models were created to mimic human symptoms through varying dosing schedules and intensities of PLD. The effects of PLD formulation parameters on HFS were also investigated. The results demonstrated that replacing ammonium sulfate with citric buffer, increasing liposome size, or reducing DSPE-mPEG
2000 modification density alleviated HFS. Additionally, liposomes without DSPE-mPEG2000 modification completely avoided HFS, suggesting that PEGylated phospholipid was the key formulation parameter contributing to PLD-induced HFS. Furthermore, the correlation between liposome pharmacokinetics and HFS indicated that PEGylation, rather than the extended circulation time of liposomes, may mediated PLD-related HFS. Better understanding of the formulation parameters that trigger HFS can guide reformulation strategies to mitigate or prevent this syndrome., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF